490 related articles for article (PubMed ID: 28988289)
1. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
[TBL] [Abstract][Full Text] [Related]
3. Whole-body magnetic resonance imaging of Li-Fraumeni syndrome patients: observations from a two rounds screening of Brazilian patients.
Paixão D; Guimarães MD; de Andrade KC; Nóbrega AF; Chojniak R; Achatz MI
Cancer Imaging; 2018 Aug; 18(1):27. PubMed ID: 30107858
[TBL] [Abstract][Full Text] [Related]
4. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.
Mai PL; Khincha PP; Loud JT; DeCastro RM; Bremer RC; Peters JA; Liu CY; Bluemke DA; Malayeri AA; Savage SA
JAMA Oncol; 2017 Dec; 3(12):1640-1645. PubMed ID: 28772286
[TBL] [Abstract][Full Text] [Related]
5. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic
Bancroft EK; Saya S; Brown E; Thomas S; Taylor N; Rothwell J; Pope J; Chamberlain A; Page E; Benafif S; Hanson H; Dias A; Mikropoulos C; Izatt L; Side L; Walker L; Donaldson A; Cook JA; Barwell J; Wiles V; Limb L; Eccles DM; Leach MO; Shanley S; Gilbert FJ; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA; Walker LG
J Med Genet; 2020 Apr; 57(4):226-236. PubMed ID: 31719169
[TBL] [Abstract][Full Text] [Related]
6. Baseline Surveillance in Li-Fraumeni Syndrome Using Whole-Body Magnetic Resonance Imaging: A Meta-analysis.
Ballinger ML; Best A; Mai PL; Khincha PP; Loud JT; Peters JA; Achatz MI; Chojniak R; Balieiro da Costa A; Santiago KM; Garber J; O'Neill AF; Eeles RA; Evans DG; Bleiker E; Sonke GS; Ruijs M; Loo C; Schiffman J; Naumer A; Kohlmann W; Strong LC; Bojadzieva J; Malkin D; Rednam SP; Stoffel EM; Koeppe E; Weitzel JN; Slavin TP; Nehoray B; Robson M; Walsh M; Manelli L; Villani A; Thomas DM; Savage SA
JAMA Oncol; 2017 Dec; 3(12):1634-1639. PubMed ID: 28772291
[TBL] [Abstract][Full Text] [Related]
7. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study.
O'Neill AF; Voss SD; Jagannathan JP; Kamihara J; Nibecker C; Itriago-Araujo E; Masciari S; Parker E; Barreto M; London WB; Garber JE; Diller L
Pediatr Blood Cancer; 2018 Feb; 65(2):. PubMed ID: 29077256
[TBL] [Abstract][Full Text] [Related]
8. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
9. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
10. Whole-body MRI surveillance in TP53 carriers is perceived as beneficial with no increase in cancer worry regardless of previous cancer: Data from the Swedish TP53 Study.
Omran M; Johansson H; Lundgren C; Silander G; Stenmark-Askmalm M; Loman N; Baan A; Adra J; Kuchinskaya E; Blomqvist L; Tham E; Bajalica-Lagercrantz S; Brandberg Y;
Cancer; 2023 Mar; 129(6):946-955. PubMed ID: 36601958
[TBL] [Abstract][Full Text] [Related]
11. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
Villani A; Tabori U; Schiffman J; Shlien A; Beyene J; Druker H; Novokmet A; Finlay J; Malkin D
Lancet Oncol; 2011 Jun; 12(6):559-67. PubMed ID: 21601526
[TBL] [Abstract][Full Text] [Related]
12. Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls.
Saya S; Killick E; Thomas S; Taylor N; Bancroft EK; Rothwell J; Benafif S; Dias A; Mikropoulos C; Pope J; Chamberlain A; Gunapala R; ; Izatt L; Side L; Walker L; Tomkins S; Cook J; Barwell J; Wiles V; Limb L; Eccles D; Leach MO; Shanley S; Gilbert FJ; Hanson H; Gallagher D; Rajashanker B; Whitehouse RW; Koh DM; Sohaib SA; Evans DG; Eeles RA
Fam Cancer; 2017 Jul; 16(3):433-440. PubMed ID: 28091804
[TBL] [Abstract][Full Text] [Related]
13. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
[TBL] [Abstract][Full Text] [Related]
14. Pediatric cancer and Li-Fraumeni/Li-Fraumeni-like syndromes: a review for the pediatrician.
Giacomazzi CR; Giacomazzi J; Netto CB; Santos-Silva P; Selistre SG; Maia AL; Oliveira VZ; Camey SA; Goldim JR; Ashton-Prolla P
Rev Assoc Med Bras (1992); 2015; 61(3):282-9. PubMed ID: 26248253
[TBL] [Abstract][Full Text] [Related]
15. Surveillance in Germline TP53 Mutation Carriers Utilizing Whole-Body Magnetic Resonance Imaging.
Ballinger ML; Ferris NJ; Moodie K; Mitchell G; Shanley S; James PA; Thomas DM
JAMA Oncol; 2017 Dec; 3(12):1735-1736. PubMed ID: 28772290
[TBL] [Abstract][Full Text] [Related]
16. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
[TBL] [Abstract][Full Text] [Related]
17. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
[TBL] [Abstract][Full Text] [Related]
18. Surveillance recommendations for patients with germline TP53 mutations.
Ballinger ML; Mitchell G; Thomas DM
Curr Opin Oncol; 2015 Jul; 27(4):332-7. PubMed ID: 26049273
[TBL] [Abstract][Full Text] [Related]
19. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
20. Penetrance Estimates Over Time to First and Second Primary Cancer Diagnosis in Families with Li-Fraumeni Syndrome: A Single Institution Perspective.
Shin SJ; Dodd-Eaton EB; Gao F; Bojadzieva J; Chen J; Kong X; Amos CI; Ning J; Strong LC; Wang W
Cancer Res; 2020 Jan; 80(2):347-353. PubMed ID: 31719099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
